Suicide gene therapy using keratin 19 enhancer and promoter in malignant mesothelioma cells

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1405-1409

  Ishiwata, Nobuo ^a   Inase, Naohiko ^a   Fujie, Toshihide ^a   Tamaoka, Meiyo ^a   Yoshizawa, Yasuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Keratin 19; Malignant mesothelioma; Suicide gene therapy; Thymidine kinase; Tumor specific promoter

Indexed keywords

CATION; GANCICLOVIR; KERATIN; KERATIN 19; LIPOSOME; LUCIFERASE; MESSENGER RNA; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASE PAIRING; CANCER CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; ENHANCER REGION; EXPRESSION VECTOR; FEMALE; FUSION GENE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; NORTHERN BLOTTING; PERITONEUM; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE THERAPY;

ANTIVIRAL AGENTS; CELL DIVISION; ENHANCER ELEMENTS (GENETICS); FEMALE; GANCICLOVIR; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, REPORTER; HELA CELLS; HUMANS; KERATINS; LIPOSOMES; LUCIFERASES; MESOTHELIOMA; PERITONEAL NEOPLASMS; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038577001     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Musk AW, Klerk NH, Eccles JL, Hobbs MS, Armstrong BK, Layman L and McNulty JC: Wittenoom, Western Australia: a modern industrial disaster. Am J Indust Med 21: 735-747, 1992.
2. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayoub J, Shepherd FA, Evans WK, Figueredo A, Pater JL, Pringle JF and Kreisman H: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7: 1157-1168, 1989.
3. Wagner MJ, Sharp JA and Summers WC: Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1. Proc Natl Acad Sci USA 78: 1441-1445, 1981.
4. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H and Nagataki S: Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 55: 3105-3109, 1995.
5. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K, Ishitobi M and Omata M: Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 56: 1341-1345, 1996.
6. Inase N, Horita K, Tanaka M, Miyake S, Ichioka M and Yoshizawa Y: Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. Int J Cancer 85: 716-719, 2000.
7. Inase N, Miyake S, and Yoshizawa Y: Calretinin promoter for suicide gene expression in malignant mesothelioma. Anticancer Res 21: 1111-1114, 2001.
8. Broers JLL, Ramaekers FCS, Rot MK, Oostendorp T, Huysmans A, van Muijien GNP, Wagenarre SS and Vooijs GP: Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 48: 3221-3229, 1988.
9. Bonfrer JMG, Shouwink JH, Korse CM and Baas P: Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 17: 2971-2974, 1997.
10. Hu L and Gudas LJ: Activation of keratin 19 gene expression by a 3′ enhancer containing an AP1 site. J Biol Chem 269: 183-191, 1994.
11. Stasiak PC and Lane EB: Sequence of cDNA coding for human keratin 19. Nucleic Acids Res 15: 10058, 1987.
12. Eckert RL: Sequence of the human 40-kDa keratin reveals an unusual structure with very high sequence indentity to the corresponding bovine keratine. Proc Natl Acad Sci USA 85: 1114-1118, 1988.
13. Carlsson G, Gullberg B and Hafstrom L: Estimation of liver tumor volume using different formulas - An experimental study in rats. J Cancer Res Clin Oncol 105: 20-23, 1983.
14. Curiel DT, Pilewski JM and Albelda SM: Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mo Biol 14: 1-18, 1996.
15. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM and Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9: 1083-1092, 1998.
16. Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M, Elshami A, Gelfand K, Wilson JM, Kaiser LR and Albelda SM: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 9: 2121-2133, 1998.
17. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.